ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 02 Jan 2024
Last Updated on 02 Jan 2024
A- A+
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has not recommended pembrolizumab for inclusion on the MOH List of Subsidised Drugs for the adjuvant treatment of renal cell carcinoma in patients who are at increased risk of recurrence following nephrectomy or
nephrectomy with resection of metastatic lesions. The decision was based on the uncertain extent of clinical benefit and unfavourable cost-effectiveness of pembrolizumab at the price proposed by the company.
Clinical indications, subsidy class and MediShield Life claim limit for pembrolizumab are provided in the Annex.


Pembrolizumab for the adjuvant treatment of renal cell carcinoma (Published 2 Jan 2024) PES Pembrolizumab for the treatment of renal cell carcinoma after kidney surgery (Published 2 Jan 2024)